Picture of Enliven Therapeutics logo

ELVN — Enliven Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapNeutral

Enliven Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

* Enliven Therapeutics Inc  ELVN.OQ  reported a quarterly
adjusted
loss of 48 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -51 cents.  The mean expectation of
eight analysts for the quarter was for a loss of 50 cents per
share. Wall Street expected results to range from -55 cents
to -44 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Enliven Therapeutics Inc's reported EPS for the quarter
was a
loss of 48 cents​.
    * The company reported a quarterly loss of $23.16 million.
    * Enliven Therapeutics Inc shares had risen by 6.4% this
quarter and gained 96.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Enliven
Therapeutics Inc is 36.50 
This summary was machine generated from LSEG data November 14 at
04:17 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.50          -0.48          Beat
 Jun. 30 2024      -0.55          -0.41          Beat
 Mar. 31 2024      -0.57          -0.54          Beat
 Dec. 31 2023      -0.54          -0.47          Beat

Recent news on Enliven Therapeutics

See all news